ImPrEP LEN Brazil (current phase)
Continuing the previous phases of implementing pre-exposure prophylaxis (PrEP) in Latin America, the ImPrEP LEN Brazil study aims to evaluate, through spontaneous PrEP seeking or HIV testing, the feasibility of implementing semi-annual injectable lenacapavir in the Brazilian Unified Health System (SUS).
LEN is not yet available in the SUS.
Target Population
The ImPrEP LEN Brazil study targets populations most vulnerable to HIV, such as gay, bisexual, and other men who have sex with cisgender men, transgender and non-binary people assigned male at birth, aged 16 to 30, with or without prior PrEP use. The study will initially be offered to 1,200 participants in seven Brazilian cities: Rio de Janeiro, Nova Iguaçu, São Paulo, Campinas, Salvador, Florianópolis, and Manaus.
The study is funded by Unitaid, with support from the Evandro Chagas National Institute of Infectious Diseases (FIOCRUZ) and the Ministry of Health, as well as a donation of the medication from Gilead Sciences.
ImPrEP Project (initial phase)
The initial phase of the ImPrEP project was carried out in Brazil, Mexico and Peru, from 2018 to 2021, with the general objective of addressing strategic aspects regarding the implementation of oral and daily HIV pre-exposure prophylaxis (PrEP) as public policy in the three countries, through the provision of pills during the first consultation.
ImPrEP CAB Brazil Project (second phase)
The second phase of the project has as its main highlight the ImPrEP CAB Brasil implementation study which aims, based on the good results obtained in the initial phase of the project, to continue offering oral prophylaxis, but also to present cabotegravir as an alternative to those interested in participating in the study. long-acting injectable – CAB LA (long action), also known as injectable PrEP.